Last reviewed · How we verify
sibling umbilical cord blood
At a glance
| Generic name | sibling umbilical cord blood |
|---|---|
| Sponsor | Joanne Kurtzberg, MD |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 (PHASE3)
- General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery
- Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood (PHASE2)
- Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries
- Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study (NA)
- TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT (NA)
- Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies (NA)
- Platform for the Prospective Mother-child Study of the Determinants of Neurodevelopmental Disorders
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sibling umbilical cord blood CI brief — competitive landscape report
- sibling umbilical cord blood updates RSS · CI watch RSS
- Joanne Kurtzberg, MD portfolio CI